General Pathology — MCQs

General Pathology Indian Medical PG Practice Questions and MCQs

Question 1021: Which of the following is NOT an autosomal dominant disorder?

A. Polycystic kidney disease
B. Ehlers-Danlos syndrome
C. Osteogenesis imperfecta
D. Alkaptonuria (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. Alkaptonuria**. In medical genetics, most **enzyme deficiencies** are inherited in an **Autosomal Recessive (AR)** pattern [1], whereas structural protein defects often follow an Autosomal Dominant (AD) pattern [2]. 1. **Why Alkaptonuria is correct:** Alkaptonuria is an **Autosomal Recessive** metabolic disorder caused by a deficiency of the enzyme **homogentisate oxidase** [1]. This leads to the accumulation of homogentisic acid, resulting in the classic triad of dark urine (on standing), ochronosis (blue-black pigmentation of connective tissue), and debilitating arthritis. 2. **Why other options are incorrect:** * **Polycystic Kidney Disease (ADPKD):** The adult form (linked to PKD1 and PKD2 genes) is a classic **AD** disorder. (Note: The infantile form, ARPKD, is recessive). * **Ehlers-Danlos Syndrome (EDS):** While genetically heterogeneous, the most common types (like the Classical and Hypermobility types) are inherited as **AD** traits affecting collagen synthesis [1]. * **Osteogenesis Imperfecta (OI):** Most cases (Type I-IV) result from mutations in COL1A1 or COL1A2 and are inherited in an **AD** fashion, leading to "brittle bone disease." **NEET-PG High-Yield Pearls:** * **Mnemonic for AD disorders:** "**V**ery **P**owerful **M**nemonic **H**elps **O**ut **A**ll **S**tudents" (**V**on Willebrand, **P**olyposis coli, **M**arfan/Myotonic dystrophy, **H**untington/Hereditary Spherocytosis, **O**steogenesis Imperfecta, **A**chondroplasia/ADPKD, **S**tatins/Familial Hypercholesterolemia). * **Alkaptonuria "Black" signs:** Black urine, Black cartilage (ochronosis), and Black heart valves. * **Rule of Thumb:** If the pathology involves a **structural protein** (Collagen, Spectrin, Fibrillin), think **AD**. If it involves an **enzyme** (HGO, Phenylalanine hydroxylase), think **AR** [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 150-151. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 57-58.

Question 1022: In-situ DNA nick end labeling can quantitate:

A. Fraction of cells in apoptotic pathways (Correct Answer)
B. Fraction of cells in S phase
C. p53 gene product
D. bcr/abl gene

Explanation: **Explanation:** **In-situ DNA nick end labeling**, commonly known as the **TUNEL assay** (Terminal deoxynucleotidyl transferase dUTP Nick End Labeling), is a specialized technique used to detect and quantitate cells undergoing **apoptosis**. **Why Option A is correct:** A hallmark of apoptosis is the activation of endogenous endonucleases, which cleave genomic DNA into fragments (internucleosomal cleavage). This process creates numerous "nicks" or free 3'-hydroxyl (3'-OH) ends. The TUNEL assay uses the enzyme **Terminal deoxynucleotidyl transferase (TdT)** to attach labeled nucleotides (like dUTP) to these 3'-OH ends. Because necrotic cells have random, irregular DNA breakdown and healthy cells have intact DNA, the concentration of labeled ends specifically identifies the fraction of cells in the apoptotic pathway. **Why other options are incorrect:** * **Option B:** The fraction of cells in the S phase is typically measured using **flow cytometry** (DNA content analysis) or **BrdU labeling**. * **Option C:** p53 gene products (proteins) are usually detected via **Immunohistochemistry (IHC)** or Western Blotting. * **Option D:** The *bcr/abl* fusion gene (associated with CML) is detected using **FISH** (Fluorescence In Situ Hybridization) or **RT-PCR**. **High-Yield Clinical Pearls for NEET-PG:** * **DNA Laddering:** On agar gel electrophoresis, apoptotic DNA appears as a "ladder" (multiples of 180-200 bp), whereas necrotic DNA appears as a diffuse "smear." * **Annexin V:** Another marker for apoptosis; it binds to **Phosphatidylserine**, which flips from the inner to the outer leaflet of the plasma membrane during early apoptosis. * **Caspase-3:** Known as the "Executioner Caspase," its activation is a definitive marker for the commitment to apoptosis.

Question 1023: Which anticoagulant is the choice for anticoagulation testing?

A. Heparin
B. EDTA
C. Sodium oxalate
D. 3.2% trisodium citrate (Correct Answer)

Explanation: **Explanation:** The correct answer is **3.2% trisodium citrate** because it is the standard anticoagulant for coagulation studies (PT, APTT, and Factor assays). **Mechanism:** Citrate works by **chelating (binding) calcium ions**, which are essential cofactors in the coagulation cascade [1]. It is preferred for testing because its action is easily reversible by adding calcium back to the plasma during the assay. The **3.2% concentration (0.109 mol/L)** is specifically recommended by international standards because it maintains the stability of Factors V and VIII better than higher concentrations and ensures accurate results even if the patient’s hematocrit is slightly elevated. The standard mixing ratio is **9 parts blood to 1 part anticoagulant.** **Why other options are incorrect:** * **Heparin:** It acts by activating antithrombin III, which inhibits thrombin and Factor Xa. It is used for arterial blood gases and some chemistry tests but is contraindicated for coagulation profiles as it directly interferes with the test results. * **EDTA:** While it is the choice for hematology (CBC/ESR) due to excellent cell morphology preservation, it irreversibly inhibits the coagulation cascade and can lead to the deterioration of Factors V and VIII. * **Sodium Oxalate:** This was used historically but is now obsolete for coagulation testing as it can cause distortion of cellular morphology and is less effective at stabilizing clotting factors compared to citrate. **High-Yield Clinical Pearls for NEET-PG:** * **Tube Color:** Citrate is found in the **Light Blue** top tube. * **The 9:1 Ratio:** Inadequate filling of the tube (under-filling) leads to an excess of citrate, causing falsely prolonged PT and APTT results. * **Polycythemia:** If a patient’s hematocrit is >55%, the volume of citrate must be adjusted (decreased) to avoid over-anticoagulation of the small plasma volume. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, pp. 128-130.

Question 1024: Which of the following is an example of a gain-of-function mutation?

A. Osteogenesis imperfecta
B. Ehlers-Danlos syndrome
C. Marfan syndrome
D. Huntington's disease (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Huntington’s Disease** **Why it is correct:** A **gain-of-function mutation** occurs when a genetic change confers a new, often toxic, activity on a protein or increases its normal activity. Huntington’s disease is a classic example of a **trinucleotide repeat expansion (CAG)** in the *HTT* gene [2]. This results in an abnormally long polyglutamine tract in the huntingtin protein. The mutant protein undergoes misfolding and forms intranuclear aggregates that are directly toxic to neurons (particularly in the striatum), representing a "gain" of a pathological function rather than a simple loss of normal function [1]. **Why the other options are incorrect:** * **A, B, and C (Osteogenesis imperfecta, Ehlers-Danlos, and Marfan syndrome):** These are primarily examples of **dominant-negative effects** or **haploinsufficiency** [3]. In these connective tissue disorders, the mutation typically results in the production of a defective structural protein (like Collagen or Fibrillin-1) that interferes with the assembly of the normal protein produced from the wild-type allele. This leads to a functional deficiency of the structural matrix, which is fundamentally a loss of structural integrity. **High-Yield Clinical Pearls for NEET-PG:** * **Huntington’s Disease:** Inherited in an **Autosomal Dominant** fashion with **Anticipation** (symptoms appear earlier in successive generations, usually via paternal transmission) [3]. * **CAG Repeat:** Remember the mnemonic "**C**audate **A**trophy; **G**lutamate toxicity." * **Gain-of-function** is most commonly associated with autosomal dominant conditions and proto-oncogenes (e.g., *RAS*, *BCR-ABL*). * **Loss-of-function** is the hallmark of most autosomal recessive diseases and tumor suppressor genes (e.g., *RB*, *TP53*). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Central Nervous System, pp. 1299-1300. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, p. 177. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 149-150.

Question 1025: All the following occur in hemostasis except?

A. Vasospasm of blood vessel
B. Platelet plug formation
C. Dissolution of clot by plasmin
D. None of the above (Correct Answer)

Explanation: **Explanation:** Hemostasis is the physiological process by which the body stops bleeding at the site of vascular injury. It is a tightly regulated sequence of events involving the vessel wall, platelets, and coagulation factors. **1. Why "None of the above" is correct:** The question asks which of the listed options does **not** occur in hemostasis. However, all three options (A, B, and C) are integral components of the hemostatic process. Therefore, none of the statements are incorrect. **2. Analysis of Options:** * **Vasospasm (Vasoconstriction):** This is the immediate, transient response to vascular injury mediated by reflex neurogenic mechanisms and the release of endothelin. It reduces blood flow to the injured area [1]. * **Platelet plug formation (Primary Hemostasis):** Platelets adhere to exposed subendothelial collagen via von Willebrand Factor (vWF), undergo activation/secretion, and aggregate to form a temporary primary hemostatic plug [2]. * **Dissolution of clot by plasmin (Fibrinolysis):** Once the vessel is repaired, the clot must be removed to restore normal blood flow [1]. Plasminogen is converted to **plasmin** (by tPA), which cleaves fibrin, leading to clot dissolution. This is the final stage of the hemostatic control mechanism [1]. **Clinical Pearls for NEET-PG:** * **Sequence of Hemostasis:** 1. Arteriolar Vasoconstriction → 2. Primary Hemostasis (Platelet plug) → 3. Secondary Hemostasis (Fibrin deposition via coagulation cascade) → 4. Clot stabilization and Resorption (Fibrinolysis) [1]. * **vWF** acts as a bridge between platelet GpIb receptors and subendothelial collagen [2]. * **Fibrinogen** binds to GpIIb/IIIa receptors to facilitate platelet aggregation [2]. * **D-dimer** is a clinical marker of fibrinolysis, representing the breakdown products of cross-linked fibrin. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, pp. 126-128. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, p. 128.

Question 1026: Which of the following is an apoptosis inhibitor gene?

A. p53
B. BCL-2 (Correct Answer)
C. Rb
D. c-myc

Explanation: **Explanation:** Apoptosis (programmed cell death) is regulated by a balance between pro-apoptotic and anti-apoptotic proteins [4]. **BCL-2** is the prototypical **anti-apoptotic (inhibitor) gene** [1]. It resides in the outer mitochondrial membrane and functions by maintaining membrane integrity, preventing the leakage of Cytochrome C into the cytosol. By inhibiting the release of Cytochrome C, BCL-2 prevents the activation of caspases, thereby halting the intrinsic pathway of apoptosis [2]. **Analysis of Incorrect Options:** * **p53 (Option A):** Known as the "Guardian of the Genome," p53 is a tumor suppressor gene that **promotes apoptosis** when DNA damage is irreparable by upregulating pro-apoptotic proteins like BAX and PUMA [5]. * **Rb (Option B):** The Retinoblastoma (Rb) gene is a tumor suppressor that regulates the cell cycle (G1 to S phase transition). It does not directly inhibit apoptosis but controls cell proliferation. * **c-myc (Option D):** This is a proto-oncogene that promotes cell proliferation. Interestingly, while it drives the cell cycle, it can also trigger apoptosis if growth factors are deficient [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Follicular Lymphoma:** Characterized by the **t(14;18)** translocation, which leads to the overexpression of BCL-2, making the B-cells immortal and resistant to apoptosis [3]. * **Pro-apoptotic members (Pro-death):** BAX and BAK (form pores in mitochondria). * **BH3-only proteins (Sensitizers):** BIM, BID, and BAD (neutralize BCL-2). * **Caspase-9** is the initiator caspase for the intrinsic (mitochondrial) pathway, while **Caspase-8** is for the extrinsic (death receptor) pathway [4]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 310. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 65-67. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 310-311. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 64-65. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 303-304.

Question 1027: Partial or complete obstruction of some part of the cardiovascular system by a foreign body transported by the bloodstream is termed as:

A. Thrombosis
B. Coagulation
C. Ischaemia
D. Embolism (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Embolism** **Why it is correct:** An **embolus** is defined as a detached intravascular solid, liquid, or gaseous mass that is carried by the blood to a site distant from its point of origin. The process of its transport and subsequent lodgement, leading to partial or complete vascular occlusion, is termed **embolism**. Most emboli (99%) represent dislodged parts of a thrombus (thromboembolism), but they can also be composed of fat globules, air bubbles, amniotic fluid, or foreign bodies [1]. **Why other options are incorrect:** * **A. Thrombosis:** This refers to the formation of a solid mass (thrombus) from blood constituents within the intact vascular system [2]. Unlike an embolism, a thrombus is **stationary** at its site of formation. * **B. Coagulation:** This is the physiological process by which blood changes from a liquid to a gel, forming a blood clot. It is a biochemical cascade rather than a mechanical obstructive event. * **C. Ischaemia:** This is a **consequence** of obstruction, not the process itself. It refers to inadequate blood supply to an organ or part of the body, especially the heart muscles or brain, leading to oxygen deprivation. **High-Yield Clinical Pearls for NEET-PG:** * **Most common source of Pulmonary Embolism:** Deep Vein Thrombosis (DVT) of the lower limbs (above the knee) [1]. * **Fat Embolism Syndrome:** Classically presents with the triad of dyspnea, neurological symptoms, and **petechial rashes** 24–72 hours after a long bone fracture [3]. * **Air Embolism:** Requires approximately **100 mL** of air to be clinically significant in the venous circulation. * **Caisson Disease:** A chronic form of gas embolism (decompression sickness) characterized by ischemic necrosis in the skeletal system (femur, tibia, humerus) [1]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Respiratory Tract Disease, pp. 323-324. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, pp. 136-137. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 146-147.

Question 1028: The Hess test is performed to assess which of the following?

A. Bleeding time
B. Capillary fragility (Correct Answer)
C. Clotting time
D. Prothrombin time

Explanation: **Explanation:** The **Hess test**, also known as the **Tourniquet test** or Rumpel-Leede phenomenon, is a clinical diagnostic tool used to assess **capillary fragility** and platelet function. **Why Option B is correct:** The test involves applying a blood pressure cuff to the upper arm and inflating it to a pressure midway between the systolic and diastolic blood pressure for 5 minutes. If the capillaries are fragile or if there is significant thrombocytopenia [1], the increased endovascular pressure causes blood to leak into the skin, resulting in the formation of **petechiae**. A positive test (usually >10–20 petechiae in a 2.5 cm square area) indicates increased capillary permeability or structural weakness. It is believed that capillaries of the skin are particularly prone to rupture following minor trauma and that under normal circumstances platelets seal these defects [2]. **Why other options are incorrect:** * **Bleeding Time (A):** Measures the time taken for a standardized skin wound to stop bleeding; it assesses platelet plug formation, not capillary wall integrity. * **Clotting Time (C):** Evaluates the intrinsic and common pathways of the coagulation cascade (e.g., Lee-White method), reflecting the time taken for fibrin clot formation. * **Prothrombin Time (D):** Specifically assesses the extrinsic and common pathways (Factors VII, X, V, II, and I). **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Utility:** The Hess test is most commonly used in the clinical diagnosis of **Dengue Hemorrhagic Fever (DHF)**, as per WHO criteria. * **Other Associations:** It can be positive in Vitamin C deficiency (**Scurvy**), Henoch-Schönlein purpura, and severe thrombocytopenia [1]. * **Limitation:** A positive test does not differentiate between a platelet defect and a vascular wall defect [1]. **Note:** Petechiae are punctate hemorrhages that often suggest thrombocytopenia or capillary leakage [2]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 619-621. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, p. 132.

Question 1029: Necrosis of cells is due to which of the following processes?

A. Calcium efflux from the cell
B. Fat deposition in cells
C. Water imbibition in cells
D. Enzymatic digestion (Correct Answer)

Explanation: **Explanation:** **Necrosis** is defined as a form of cell death characterized by the loss of membrane integrity and the leakage of cellular contents, leading to a local inflammatory response [1]. **Why Enzymatic Digestion is Correct:** The fundamental pathogenesis of necrosis involves two concurrent processes: 1. **Denaturation of proteins:** This leads to the characteristic eosinophilic appearance of the cytoplasm [1]. 2. **Enzymatic digestion of the cell:** This is the hallmark of necrosis. These enzymes are derived either from the lysosomes of the dying cells themselves (**autolysis**) or from the lysosomes of immigrating leukocytes (**heterolysis**) [1]. This process results in the degradation of cellular components and the nucleus (pyknosis, karyorrhexis, and karyolysis). **Analysis of Incorrect Options:** * **A. Calcium efflux from the cell:** In cell injury, there is actually an **influx** of calcium into the cell (due to failure of Ca-ATPase pumps) [2]. Increased cytosolic calcium activates phospholipases, proteases, and endonucleases, which mediate cell death [3]. * **B. Fat deposition in cells:** This refers to **Steatosis** (fatty change), which is a form of *reversible* cell injury, not a mechanism of necrosis. * **C. Water imbibition in cells:** Also known as **Hydropic swelling** or cloudy swelling. This is the *earliest* manifestation of almost all forms of reversible cell injury due to failure of the Na+/K+ ATPase pump [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Coagulative Necrosis:** The most common type; architecture is preserved (seen in all infarcts except the brain). * **Liquefactive Necrosis:** Architecture is lost; seen in **Brain infarcts** and **Abscesses** (due to high enzymatic activity). * **Apoptosis vs. Necrosis:** Unlike necrosis, apoptosis is an active, ATP-dependent process that does *not* elicit inflammation and maintains membrane integrity. * **Dystrophic Calcification:** Often occurs in areas of necrosis (e.g., Atherosclerotic plaques) despite normal serum calcium levels. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, p. 53. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 60-61. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 102-103.

Question 1030: Satellite sequences are observed during which phase of the cell cycle?

A. G0 phase (Correct Answer)
B. M phase
C. S phase
D. G1 phase

Explanation: **Explanation:** **Satellite sequences** refer to highly repetitive DNA sequences (often found in heterochromatin) that do not code for proteins but play a crucial role in chromosome structure. [2] 1. **Why G0 is the correct answer:** In the **G0 (quiescent) phase**, the cell is metabolically active but has exited the cell cycle. [1], [4] During this stage, the chromatin is highly condensed. Satellite DNA sequences are primarily located in the **centromeric and pericentromeric regions** of chromosomes. These sequences are most distinctly observed and organized as "satellite bodies" or "chromocenters" during the interphase, particularly in the G0 state, where they contribute to the structural silencing of genes and nuclear organization. 2. **Why other options are incorrect:** * **M phase (Mitosis):** While chromosomes are most visible here, they are in their most condensed mitotic form. The term "satellite sequences" in the context of specific interphase observation refers to their organizational state in non-dividing cells. * **S phase (Synthesis):** This is the phase of DNA replication. [3] Satellite DNA is typically "late-replicating," but the active unwinding of DNA for replication makes these sequences less distinct as structural markers. * **G1 phase:** This is a gap phase for cell growth. While present, satellite sequences are most characteristic of the stable, non-cycling G0 population in many histopathological studies. **High-Yield Clinical Pearls for NEET-PG:** * **Satellite DNA** is a type of Non-coding DNA. [2] * **Minisatellites (VNTRs):** Used in DNA fingerprinting (10-60 bp). * **Microsatellites (STRs):** Used in linkage analysis and diagnosing **Lynch Syndrome** (MSI - Microsatellite Instability). * **Heterochromatin:** Satellite sequences are a hallmark of constitutive heterochromatin (stained by C-banding). [2] **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. With Illustrations By, pp. 37-38. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 54-55. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 78-79. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 79-80.

Practice by Chapter

Cell Injury and Cell Death

Practice Questions

Adaptations of Cellular Growth

Practice Questions

Accumulations and Deposits

Practice Questions

Acute and Chronic Inflammation

Practice Questions

Tissue Repair and Wound Healing

Practice Questions

Hemodynamic Disorders

Practice Questions

Genetic Disorders

Practice Questions

Environmental Pathology

Practice Questions

Nutritional Diseases

Practice Questions

Molecular Basis of Disease

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free